Acadia Pharmaceuticals (ACAD) PT Raised to $54 at Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $20.57 --0%
Rating Summary:
16 Buy, 11 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
16 Buy, 11 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Jefferies analyst Chris Howerton raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $54.00 (from $53.00) while maintaining a Buy rating.
You May Also Be Interested In
- Citi Downgrades Bank Rakyat Indonesia Persero Tbk PT (BBRI:IJ) (BKRKF) to Neutral
- Bharat Electronics Ltd (BHE:IN) PT Lowered to INR470 at Axis Capital Limited
- Goldman Sachs Upgrades Chengdu XGimi Technology Co Ltd (688696:CH) to Neutral
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
